601544 Disclosed is a pharmaceutical combination comprising: (i) a PDGF-B antagonist； and (ii) a VEGF-A antagonist； wherein the PDGF-B antagonist is a pegylated or unpegylated aptamer having the sequence: CAGGCUACGN CGTAGAGCAU CANTGATCCU GT having 2'-fluoro-2'deoxyuridine at positions 6, 20 and 30； 2'fluoro-2'-deoxycytidine at positions 8,21,28 and 29； 2'-O-Methyl-2'-deoxyguanosine at positions 9,15,17 and 31； 2'-O-Methyl-2'-deoxyadenosine at position 22； "N" in positions 10 and 23 from a hexaethylene-glycol phosphoramidite and an inverted orientation T at position 32； and the VEGF-A antagonist is an antibody or binding fragment thereof； and wherein the PDGF-B antagonist and VEGF-A antagonist are formulated for sequential or simultaneous administration to a patient. Further disclosed is the use of said PDGF-? antagonist in the manufacture of a medicament for sequential or simultaneous administration with a VEGF-A antagonist as described above for treating an ocular neovascular disorder.
